Severe endothelial dysfunction in the aorta of a mouse model of Fabry disease; partial prevention by N-butyldeoxynojirimycin treatment.

Severe endothelial dysfunction in the aorta of a mouse model of Fabry disease; partial prevention by N-butyldeoxynojirimycin treatment.

OBJECTIVE: Fabry disease results from alpha-gala-ctosidase A deficiency and is characterized by the lysosomal accumulation of globotriaosylceramide. Globotriaosylceramide storage predominantly affects endothelial cells, altering vascular wall morphology and vasomotor function. Our objective was to i...

Bibliografske podrobnosti
Main Authors:	Heare, T, Alp, N, Priestman, D, Kulkarni, AB, Qasba, P, Butters, T, Dwek, R, Clarke, K, Channon, K, Platt, F
Format:	Journal article
Jezik:	English
Izdano:	2007

Podobne knjige/članki

N-butyldeoxynojirimycin causes weight loss as a result of appetite suppression in lean and obese mice.
od: Priestman, D, et al.
Izdano: (2008)

NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin.
od: Jeyakumar, M, et al.
Izdano: (2004)

N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo.
od: Andersson, U, et al.
Izdano: (2000)

Long-term non-hormonal male contraception in mice using N-butyldeoxynojirimycin.
od: Walden, C, et al.
Izdano: (2006)

The alpha-glucosidase inhibitor N-butyldeoxynojirimycin inhibits human immunodeficiency virus entry at the level of post-CD4 binding.
od: Fischer, P, et al.
Izdano: (1995)

Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis.
od: Cox, T, et al.
Izdano: (2000)

Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease.
od: Elstein, D, et al.
Izdano: (2004)

Substrate reduction therapy in mouse models of the glycosphingolipidoses.
od: Platt, F, et al.
Izdano: (2003)

N -butyldeoxynojirimycin reduces growth and ganglioside content of experimental mouse brain tumours.
od: Ranes, M, et al.
Izdano: (2001)

Restricted ketogenic diet enhances the therapeutic action of N-butyldeoxynojirimycin towards brain GM2 accumulation in adult Sandhoff disease mice.
od: Denny, C, et al.
Izdano: (2010)

N-Butyldeoxynojirimycin is a broadly effective anti-HIV therapy significantly enhanced by targeted liposome delivery.
od: Pollock, S, et al.
Izdano: (2008)

Imino sugar therapy for type 1 Gaucher disease.
od: Priestman, D, et al.
Izdano: (2000)

Increased glycosphingolipid levels in serum and aortae of apolipoprotein E gene knockout mice.
od: Garner, B, et al.
Izdano: (2002)

Glycosphingolipid profiling of tissues from mouse models of human lysosomal storage disorders
od: Priestman, D, et al.
Izdano: (2008)

Increased endothelial tetrahydrobiopterin levels by GTPCH over expression in transgenic mice prevents diabetic endothelial dysfunction
od: Alp, N, et al.
Izdano: (2003)

Implications for invariant natural killer T cell ligands due to the restricted presence of isoglobotrihexosylceramide in mammals.
od: Speak, A, et al.
Izdano: (2007)

Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy
od: Jefferson Loso, et al.
Izdano: (2018-08-01)

Endothelial Dysfunction in Fabry Disease Is Related to Glycocalyx Degradation
od: Solvey Pollmann, et al.
Izdano: (2021-11-01)

Increased glycosphingolipid levels in serum and aortae of apolipoprotein E gene knockout mice
od: Brett Garner, et al.
Izdano: (2002-02-01)

Effects of N-butyldeoxynojirimycin and the Lec3.2.8.1 mutant phenotype on N-glycan processing in Chinese hamster ovary cells: application to glycoprotein crystallization.
od: Butters, T, et al.
Izdano: (1999)

An MRI technique for the quantification of atherosclerotic lesions in the ApoE knockout mouse
od: Grieve, S, et al.
Izdano: (2002)

Anderson–Fabry Disease: From Endothelial Dysfunction to Emerging Therapies
od: Cosimo A. Stamerra, et al.
Izdano: (2021-01-01)

Inhibition of calcium uptake via the sarco/endoplasmic reticulum Ca2+-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-butyldeoxynojirimycin.
od: Pelled, D, et al.
Izdano: (2003)

High soluble endoglin levels do not induce endothelial dysfunction in mouse aorta.
od: Ivana Nemeckova, et al.
Izdano: (2015-01-01)

Endothelial nitric oxide synthase dysfunction in diabetic mice: importance of tetrahydrobiopterin in eNOS dimerisation.
od: Cai, S, et al.
Izdano: (2005)

Lucerastat, an iminosugar for substrate reduction therapy in Fabry Disease: Preclinical evidence
od: Welford, R, et al.
Izdano: (2017)

Antiviral effect of N-butyldeoxynojirimycin against bovine viral diarrhea virus correlates with misfolding of E2 envelope proteins and impairment of their association into E1-E2 heterodimers.
od: Branza-Nichita, N, et al.
Izdano: (2001)

Increased endothelial tetrahydrobiopterin synthesis by targeted transgenic GTP-cyclohydrolase I overexpression reduces endothelial dysfunction and atherosclerosis in ApoE-knockout mice.
od: Alp, N, et al.
Izdano: (2004)

N-butyldeoxynojirimycin delays motor deficits, cerebellar microgliosis, and Purkinje cell loss in a mouse model of mucolipidosis type IV
od: Lauren C. Boudewyn, et al.
Izdano: (2017-09-01)

Globotriaosylsphingosine accumulation and not alpha-galactosidase-A deficiency causes endothelial dysfunction in Fabry disease.
od: Mehdi Namdar, et al.
Izdano: (2012-01-01)

Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease.
od: Alp, N, et al.
Izdano: (2004)

Chronic treatment with flavonoids prevents endothelial dysfunction in spontaneously hypertensive rat aorta
od: Ajay, M., et al.
Izdano: (2005)

Induction of Haemeoxygenase-1 Improves FFA-Induced Endothelial Dysfunction in Rat Aorta
od: Fang Han, et al.
Izdano: (2015-02-01)

Iminosugar inhibitors for treating the lysosomal glycosphingolipidoses
od: Butters, T, et al.
Izdano: (2005)

Therapeutic applications of imino sugars in lysosomal storage disorders.
od: Butters, T, et al.
Izdano: (2003)

Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses.
od: Butters, T, et al.
Izdano: (2005)

New therapeutics for the treatment of glycosphingolipid lysosomal storage diseases.
od: Butters, T, et al.
Izdano: (2003)

Inhibition of glycosphingolipid biosynthesis: application to lysosomal storage disorders.
od: Butters, T, et al.
Izdano: (2000)

The apo E gene knockout mouse as a model to study the potential atherogenic properties of glycosphingolipids
od: Garner, B, et al.
Izdano: (2003)

Correction: Globotriaosylceramide Accumulation and Not Alpha-Galactosidase-A Deficiency Causes Endothelial Dysfunction in Fabry Disease
Izdano: (2012-01-01)